<DOC>
	<DOCNO>NCT00019708</DOCNO>
	<brief_summary>Phase I trial study effectiveness geldanamycin analogue treat patient advance solid tumor non-Hodgkin 's lymphoma . Drugs use chemotherapy work different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Geldanamycin Analogue Treating Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose geldanamycin analogue ( AAG ) patient advance solid tumor . II . To determine toxic effect drug patient population . III . To determine biochemical molecular effect drug normal accessible tumor tissue patient . IV . To determine pharmacokinetics drug patient . V. To assess antitumor activity drug patient . OUTLINE : This dose-escalation study . Patients receive geldanamycin analogue ( AAG ) IV 1-6 hour daily day 1 , 4 , 15 , 18 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 10 patient treated MTD . Patients follow every 6 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<criteria>Criteria : Platelet count least 100,000/mm^3 No leukemia No active CNS involvement tumor ECOG 02 Life expectancy : least 3 month Absolute neutrophil count least 2,000/mm^3 No New York Heart Association class III IV heart failure No history myocardial infarction within past year Bilirubin = &lt; upper limit normal ( ULN ) AST great 2 time ULN ( great 98 U/L ) No uncontrolled dysrhythmias No poorly control angina No serious ventricular arrhythmia ( i.e. , ventricular tachycardia ( VT ) ventricular fibrillation ( VF ) &gt; = 3 beat row ) QTc interval = &lt; 450 msec men = &lt; 470 msec woman LVEF &gt; = 40 % MUGA Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious medical condition would preclude study participation No serious hypersensitivity egg product No concurrent anticancer immunotherapy At least 4 week since prior chemotherapy recover No concurrent anticancer chemotherapy ( e.g. , cyclophosphamide , doxorubicin , vincristine , prednisone [ CHOP ] mechlorethamine , vincristine , procarbazine , prednisone [ MOPP ] ) No concurrent anticancer hormonal therapy Concurrent glucocorticoid antiemetic nonmalignant disease allow At least 4 week since prior radiotherapy recover No concurrent radiotherapy No concurrent major surgery No concurrent anticancer glucocorticoid Creatinine = &lt; ULN Creatinine clearance least 60 mL/min No concurrent medication cause QTc prolongation Histologically confirm advanced solid tumor curative therapy exist NonHodgkin 's lymphoma allow No concurrent drug interfere hepatic CYP3A4 metabolism ( e.g. , grapefruit juice , ketoconazole , fluconazole , itraconazole , cyclosporine , erythromycin , clarithromycin , cimetidine , terfenadine , astemizole , indinavir , nelfinavir mesylate )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>